Acute Exacerbation of Chronic Obstructive Pulmonary Disease

Warning

Duration

Duration 5 days then review.

First Line - not severe

Important: Therapy

Amoxicillin oral 500mg 8 hourly

 

Notes:

Penicillin allergy – not severe

Important: Therapy

Penicillin allergy

Doxycycline oral 200mg on first day then 100mg daily

Notes:

Acute Exacerbations of Chronic Obstructive Pulmonary Disease (COPD) - severe

Important: Therapy

Co-Amoxiclav IV 1.2g 8 hourly

Penicillin allergy – Discuss with Consultant Microbiologist

Notes:

Acute Exacerbations of Chronic Obstructive Pulmonary Disease (COPD) – severe Pseudomonal infections

Important: Therapy

1st line

Piperacillin-tazobactam IV 4.5g every 6 hours

Or, if penicillin allergy/outpatient treatment/IV to oral switch

Ciprofloxacin 750mg oral 12 hourly

Notes:

Important: Notes

Acute Exacerbation of Chronic Obstructive Pulmonary Disease

Patients with two or more of the three cardinal signs may benefit from treatment with antimicrobials

  • Increased shortness of breath
  • Increased sputum volume
  • Purulent sputum

Antimicrobials should be tailored against previous isolates where possible.

Consider sending a throat swab in viral transport medium for respiratory viral studies.

Fluroquinolones

Refer to important safety information for all quinolones prior to prescribing.

See MHRA Drug Safety Update January 2024: Fluoroquinolones must only be used in situations when other antibiotics, that are commonly recommended for the infection, are inappropriate such as:

  • there is resistance to other first-line antibiotics recommended for the infection
  • other first-line antibiotics are contraindicated in an individual patient
  • other first-line antibiotics have caused side effects in the patient requiring treatment to be stopped
  • treatment with other first-line antibiotics has failed

Duration 5 days then review

Editorial Information

Last reviewed: 01/07/2025

Next review date: 31/07/2028

Author(s): James, E, Duguid, A.

Version: 2.0

Approved By: NHS Borders Antimicrobial Management Team

Reviewer name(s): James, E, Duguid, A, Longworth, E, Taylor, J, MacKay, T, Jabbal, S, Rabinovich, R.